NCT06746402

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants

A Phase 1, Two-Part, Double-blind, Placebo-controlled, Randomized Study of the Safety, Tolerability, and Pharmacokinetics of BMS-986278 (Part A) and a Randomized, Double-blind, Positive-controlled, Placebo-controlled, 4-Period Crossover, Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986278 on Cardiac Repolarization (Part B) in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of high dose of BMS-986278 in healthy participants and to assess the effect of BMS-986278 on the ECG intervals in healthy participants.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	BMS-986278	Specified dose on specified days
DRUG	Placebo	Specified dose on specified days
DRUG	Moxifloxacin	Specified dose on specified days

Timeline

• Start date: 2025-02-10
• Primary completion: 2025-09-11
• Completion: 2025-09-11
• First posted: 2024-12-24
• Last updated: 2025-10-06

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study